Baseline Assessments Before Treatment
Check complete blood count (CBC), liver function tests (LFTs), renal function, and electrolytes prior to each cycle. Lurbinectedin, approved as Zepzelca for small cell lung cancer, causes myelosuppression as its primary dose-limiting toxicity, so establish patient's tolerance with these labs.[1][2]
Monitoring During Treatment Cycles
Perform CBC with differential and platelets on day 1 of each 21-day cycle, plus weekly during the first two cycles or if prior grade 3/4 neutropenia occurred. Delay dosing if absolute neutrophil count (ANC) <1.5 × 10^9/L or platelets <100 × 10^9/L; reduce dose for severe cytopenias. Monitor LFTs (ALT, AST, bilirubin) before each cycle due to risk of hepatotoxicity.[1][3]
Key Toxicity Signs to Watch
- Hematologic: Neutropenia (grade 4 in 32% of patients), thrombocytopenia (15%), anemia. Febrile neutropenia occurs in 2-4%; hold treatment and use G-CSF support if needed.
- Hepatic: Elevated transaminases or bilirubin; reversible but monitor closely.
- Other: Fatigue (42%), nausea (37%), decreased appetite (28%), hyperglycemia (15%). Transaminitis reported in trials; no routine cardiac monitoring required, but watch for rhabdomyolysis or pneumonitis rarely.[1][2][4]
Dose Adjustments and Management
Reduce dose from 3.2 mg/m² to 2.6 mg/m² (or 2.0 mg/m²) for grade 4 neutropenia >7 days, grade 4 thrombocytopenia, or grade 3/4 non-hematologic toxicity. Discontinue for recurrent severe issues or interstitial lung disease. Premedicate with antiemetics and dexamethasone for nausea/infusion reactions.[1][3]
Patient Education and Follow-Up
Instruct patients to report fever >100.4°F, unusual bleeding, bruising, shortness of breath, or jaundice immediately. Outpatient monitoring suffices post-infusion unless hospitalized for complications. Long-term: No specific late toxicity surveillance beyond standard oncology follow-up.[2][4]
Sources
[1]: Zepzelca (lurbinectedin) Prescribing Information
[2]: NCCN Guidelines: Small Cell Lung Cancer, Version 3.2023
[3]: FDA Approval Summary for Lurbinectedin
[4]: ATLAS Trial Data on Safety (J Clin Oncol 2021)